Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Targeted or IO-based first-line treatment of BRAF-V600-mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.
Authors
- Martin Sebastian (ORCID: https://orcid.org/0000-0002-0404-7741)
- Petros Christopoulos (ORCID: https://orcid.org/0000-0002-7966-8980)
- Nikolaj Frost (ORCID: https://orcid.org/0000-0001-7452-7129)
- Martin Wermke (ORCID: https://orcid.org/0000-0002-4844-4087)
- Maximilian Rost
- Hans‐Georg Kopp (ORCID: https://orcid.org/0000-0002-0825-8888)
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Martin Reck (ORCID: https://orcid.org/0000-0002-5348-4462)
- Christin Assmann
- Frank Griesinger (ORCID: https://orcid.org/0000-0002-6822-5498)
- Anna Kron (ORCID: https://orcid.org/0000-0002-3047-6486)
- Felix Carl Saalfeld (ORCID: https://orcid.org/0000-0002-4095-8649)
- Matthias Scheffler (ORCID: https://orcid.org/0000-0002-1280-9873)
- Moritz Hilbrandt
- Franziska Herster (ORCID: https://orcid.org/0000-0003-1512-7306)
- Julia Roeper
- Marcel Wiesweg (ORCID: https://orcid.org/0000-0002-9698-9559)
- Anna Rasokat (ORCID: https://orcid.org/0009-0008-7850-6374)
- Franziska Glanemann
- Albrecht Stenzinger
- Ali Alaffas
- Jürgen Wolf (ORCID: https://orcid.org/0000-0001-8833-8812)
- Jonas Kulhavy (ORCID: https://orcid.org/0000-0002-8837-1687)
- Cornelia Kropf-Sanchen
Institutions
- Essen University Hospital (DE)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.jtho.2025.04.016
- Citations
- 14
- Primary Topic
- Synthesis and biological activity
- Type
- article
- Field-Weighted Citation Impact
- 13.10